Evolus, Inc. (0K16.L)
USD 14.58
(0.16%)
USD 14.58
(0.16%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 63.7 Million USD | 230.49% |
| 2022 | 19.27 Million USD | 126.96% |
| 2021 | -71.51 Million USD | -300.01% |
| 2020 | 35.75 Million USD | 367.91% |
| 2019 | -13.34 Million USD | 82.5% |
| 2018 | -76.25 Million USD | -136.09% |
| 2017 | 211.32 Million USD | 254.73% |
| 2016 | 59.57 Million USD | 41.28% |
| 2015 | 42.16 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 29.69 Million USD | -53.39% |
| 2024 Q2 | 33.08 Million USD | 11.41% |
| 2023 Q3 | 56.4 Million USD | 2.34% |
| 2023 Q4 | 63.7 Million USD | 12.94% |
| 2023 FY | 63.7 Million USD | 230.49% |
| 2023 Q1 | 42.85 Million USD | 122.32% |
| 2023 Q2 | 55.11 Million USD | 28.61% |
| 2022 FY | 19.27 Million USD | 126.96% |
| 2022 Q3 | 8.93 Million USD | 190.35% |
| 2022 Q4 | 19.27 Million USD | 115.67% |
| 2022 Q2 | -9.89 Million USD | 69.09% |
| 2022 Q1 | -32 Million USD | 55.25% |
| 2021 Q3 | -84.1 Million USD | 22.22% |
| 2021 FY | -71.51 Million USD | -300.01% |
| 2021 Q2 | -108.13 Million USD | -8139.85% |
| 2021 Q1 | 1.34 Million USD | -96.24% |
| 2021 Q4 | -71.51 Million USD | 14.97% |
| 2020 FY | 35.75 Million USD | 367.91% |
| 2020 Q1 | 62.31 Million USD | 566.95% |
| 2020 Q2 | 67.59 Million USD | 8.47% |
| 2020 Q3 | 52.36 Million USD | -22.53% |
| 2020 Q4 | 35.75 Million USD | -31.72% |
| 2019 Q1 | 36.17 Million USD | 147.44% |
| 2019 FY | -13.34 Million USD | 82.5% |
| 2019 Q4 | -13.34 Million USD | -123.43% |
| 2019 Q3 | 56.95 Million USD | -12.59% |
| 2019 Q2 | 65.15 Million USD | 80.13% |
| 2018 Q3 | -88.37 Million USD | -225.93% |
| 2018 FY | -76.25 Million USD | -136.09% |
| 2018 Q2 | -27.11 Million USD | 18.87% |
| 2018 Q1 | -33.42 Million USD | -115.81% |
| 2018 Q4 | -76.25 Million USD | 13.71% |
| 2017 FY | 211.32 Million USD | 254.73% |
| 2017 Q1 | - USD | -100.0% |
| 2017 Q2 | 191.02 Million USD | 0.0% |
| 2017 Q3 | 40.61 Million USD | -78.74% |
| 2017 Q4 | 211.32 Million USD | 420.33% |
| 2016 FY | 59.57 Million USD | 41.28% |
| 2016 Q4 | 59.76 Million USD | 0.0% |
| 2015 FY | 42.16 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | 161.882% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 304.081% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 67.835% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -99.806% |
| bluebird bio, Inc. | 108.57 Million USD | 41.321% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 806.61% |
| Imunon, Inc. | -4.69 Million USD | 1455.699% |
| Editas Medicine, Inc. | -87.11 Million USD | 173.13% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 99.504% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 96.963% |
| Myriad Genetics, Inc. | 88.1 Million USD | 27.687% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 64.068% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 290.02% |
| Verastem, Inc. | -37.27 Million USD | 270.9% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 99.226% |
| Waters Corporation | 1.96 Billion USD | 96.75% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 99.763% |
| Biogen Inc. | 6.28 Billion USD | 98.987% |
| Nektar Therapeutics | 210.24 Million USD | 69.697% |
| Perrigo Company plc | 3.32 Billion USD | 98.082% |
| Dynavax Technologies Corporation | 106.63 Million USD | 40.256% |
| Illumina, Inc. | 1.21 Billion USD | 94.752% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -814.284% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 155.939% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 56.086% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -786.434% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 83.179% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 997.296% |
| Adicet Bio, Inc. | -142 Million USD | 144.862% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 273.101% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 335.085% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 86.111% |
| FibroGen, Inc. | 56.76 Million USD | -12.227% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 94.436% |
| OPKO Health, Inc. | 230.68 Million USD | 72.383% |
| Homology Medicines, Inc. | 18.43 Million USD | -245.544% |
| Geron Corporation | 14.76 Million USD | -331.597% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 95.981% |
| Exelixis, Inc. | -73.05 Million USD | 187.211% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 217.421% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 142.184% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 157.187% |
| Zoetis Inc. | 4.76 Billion USD | 98.662% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 131.883% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 732.589% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 100.666% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 537.195% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 93.957% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 93.421% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 147.052% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 95.386% |
| Blueprint Medicines Corporation | 702.83 Million USD | 90.936% |
| Insmed Incorporated | 721.62 Million USD | 91.172% |
| TG Therapeutics, Inc. | 17.86 Million USD | -256.668% |
| Incyte Corporation | -3.17 Billion USD | 102.006% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 91.681% |